Latest News Digital Diagnostics, Formerly IDx, Provides New Designation to Two Top Executives By Staff Tuesday, January 18, 2022 12:18 AM A patient receiving an exam with the IDx-DR system, an autonomous AI diagnostic system for the detection of diabetic retinopathy and diabetic macular edema at the point-of-care. CORALVILLE, Iowa—Digital Diagnostics recently announced the designation of co-founder has been given to the company’s CEO and president/COO, John Bertrand and Seth Rainford, respectively after a board vote. The new designations follow the company name change from IDx to Digital Diagnostics. These C-suite updates recognize the growth plans and innovation as the company seeks to advance the use of artificial intelligence (AI) across additional clinical applications. “John and Seth have the vision to make Digital Diagnostics a world-class leader in health care diagnostic testing,” said Michael Abramoff, MD, PhD, founder and executive chairman of Digital Diagnostics. “I created the IDx-DR product because I recognized a gap in diabetic patient care. As an ophthalmologist, it pained me to see how diabetic retinopathy was not only robbing patients of their eyesight, but also their livelihood. IDx-DR was the solution to closing the care gap and getting this necessary screening done at point-of-care.Under John and Seth’s leadership, we are getting IDx-DR into the health systems and communities with high indices of diabetes and improving patient care. However, IDx-DR is only the beginning and our leaders have an aggressive road map of product development to scale across specialties.” Digital Diagnostics created IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (DR) and diabetic macular edema (DME) at the point-of-care. The platform includes two autonomous AI systems, IDx-DR and DermSpot. The company works closely with patient advocacy groups, federal regulators, and other quality of care and ethics-focused stakeholders to enable adoption of autonomous AI.